X Cortes1, J Borrás-Blasco2, B Antequera3, S Fernandez-Martinez4, E Casterá2, S Martin5, J R Molés1. 1. Gastroenterology Section, Internal Medicine, Hospital de Sagunto, Sagunt, Spain. 2. Pharmacy Service, Hospital de Sagunto, Sagunt, Spain. 3. Internal Medicine, Hospital de Sagunto, Sagunt, Spain. 4. Preventive Medicine Unit, Hospital de Sagunto, Sagunt, Spain. 5. Pediatric Service, Hospital de Sagunto, Sagunt, Spain.
Abstract
WHAT IS KNOWN AND OBJECTIVES: The safety of continued ustekinumab (UST) therapy during pregnancy remains unclear in patients with Crohn's disease (CD). There are no meta-analysis reports of exposure to UST during pregnancy. The objective was to describe a case of a pregnant patient with CD who was successfully treated with UST maintenance therapy throughout the pregnancy and delivered a baby boy without any congenital malformations, neurological abnormalities or birth defects. CASE SUMMARY: A 37-year-old patient with CD treated with UST became pregnant. She had been receiving UST for 8 months at the time. After discussion with the patient and the obstetric team, the UST therapy was continued. The result of treatment was an uneventful pregnancy with delivery, at term, of a healthy boy and the maintenance of clinical, biological and endoscopic remission of CD during and after pregnancy. WHAT IS NEW AND CONCLUSION: To our knowledge, this is the first reported use of continued UST therapy for CD throughout a pregnancy. The result of treatment was an uncomplicated pregnancy with the mother giving birth to a healthy boy at term and the maintenance of clinical biological and endoscopic remission of CD during and after pregnancy.
WHAT IS KNOWN AND OBJECTIVES: The safety of continued ustekinumab (UST) therapy during pregnancy remains unclear in patients with Crohn's disease (CD). There are no meta-analysis reports of exposure to UST during pregnancy. The objective was to describe a case of a pregnant patient with CD who was successfully treated with UST maintenance therapy throughout the pregnancy and delivered a baby boy without any congenital malformations, neurological abnormalities or birth defects. CASE SUMMARY: A 37-year-old patient with CD treated with UST became pregnant. She had been receiving UST for 8 months at the time. After discussion with the patient and the obstetric team, the UST therapy was continued. The result of treatment was an uneventful pregnancy with delivery, at term, of a healthy boy and the maintenance of clinical, biological and endoscopic remission of CD during and after pregnancy. WHAT IS NEW AND CONCLUSION: To our knowledge, this is the first reported use of continued UST therapy for CD throughout a pregnancy. The result of treatment was an uncomplicated pregnancy with the mother giving birth to a healthy boy at term and the maintenance of clinical biological and endoscopic remission of CD during and after pregnancy.
Authors: C Venturin; S Nancey; P Danion; M Uzzan; M Chauvenet; C Bergoin; X Roblin; B Flourié; G Boschetti Journal: BMC Gastroenterol Date: 2017-06-19 Impact factor: 3.067
Authors: Sailish Honap; Susanna Meade; Hajir Ibraheim; Peter M Irving; Michael P Jones; Mark A Samaan Journal: Dig Dis Sci Date: 2021-03-16 Impact factor: 3.199
Authors: María Chaparro; María G Donday; Francisco Abad-Santos; Francisco Javier Martín de Carpi; Miguel Ángel Maciá-Martínez; Dolores Montero; Diana Acosta; Yanire Brenes; Javier P Gisbert Journal: Therap Adv Gastroenterol Date: 2021-06-03 Impact factor: 4.409